CN110025609A - 用于治疗中风的佛波醇酯的组合物和使用方法 - Google Patents

用于治疗中风的佛波醇酯的组合物和使用方法 Download PDF

Info

Publication number
CN110025609A
CN110025609A CN201910197159.XA CN201910197159A CN110025609A CN 110025609 A CN110025609 A CN 110025609A CN 201910197159 A CN201910197159 A CN 201910197159A CN 110025609 A CN110025609 A CN 110025609A
Authority
CN
China
Prior art keywords
phorbol
acid esters
deoxidation
acetic acid
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910197159.XA
Other languages
English (en)
Chinese (zh)
Inventor
韩正涛
程宏峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biosuccess Biotech Co Ltd
Original Assignee
Biosuccess Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosuccess Biotech Co Ltd filed Critical Biosuccess Biotech Co Ltd
Publication of CN110025609A publication Critical patent/CN110025609A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/33—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with hydroxy compounds having more than three hydroxy groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
CN201910197159.XA 2012-01-18 2013-01-18 用于治疗中风的佛波醇酯的组合物和使用方法 Pending CN110025609A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261588162P 2012-01-18 2012-01-18
US201261588167P 2012-01-18 2012-01-18
US201261588165P 2012-01-18 2012-01-18
US61/588,167 2012-01-18
US61/588,165 2012-01-18
US61/588,162 2012-01-18
CN201380014858.7A CN104168957A (zh) 2012-01-18 2013-01-18 用于治疗中风的佛波醇酯的组合物和使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380014858.7A Division CN104168957A (zh) 2012-01-18 2013-01-18 用于治疗中风的佛波醇酯的组合物和使用方法

Publications (1)

Publication Number Publication Date
CN110025609A true CN110025609A (zh) 2019-07-19

Family

ID=48799818

Family Applications (4)

Application Number Title Priority Date Filing Date
CN201380014940.XA Pending CN104507466A (zh) 2012-01-18 2013-01-18 佛波醇酯的组合物和使用方法
CN201380014858.7A Pending CN104168957A (zh) 2012-01-18 2013-01-18 用于治疗中风的佛波醇酯的组合物和使用方法
CN201910197159.XA Pending CN110025609A (zh) 2012-01-18 2013-01-18 用于治疗中风的佛波醇酯的组合物和使用方法
CN201810918599.5A Pending CN108969514A (zh) 2012-01-18 2013-01-18 佛波醇酯的组合物和使用方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN201380014940.XA Pending CN104507466A (zh) 2012-01-18 2013-01-18 佛波醇酯的组合物和使用方法
CN201380014858.7A Pending CN104168957A (zh) 2012-01-18 2013-01-18 用于治疗中风的佛波醇酯的组合物和使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201810918599.5A Pending CN108969514A (zh) 2012-01-18 2013-01-18 佛波醇酯的组合物和使用方法

Country Status (18)

Country Link
US (1) US20170096386A1 (enExample)
EP (2) EP2804669B1 (enExample)
JP (5) JP6336914B2 (enExample)
KR (4) KR102102640B1 (enExample)
CN (4) CN104507466A (enExample)
AU (7) AU2013287280B2 (enExample)
BR (2) BR112014017650B1 (enExample)
CA (3) CA2861459C (enExample)
IL (2) IL233674B (enExample)
MX (4) MX389510B (enExample)
MY (5) MY176593A (enExample)
NZ (4) NZ726666A (enExample)
PH (10) PH12014501656B1 (enExample)
RU (3) RU2659684C2 (enExample)
SG (12) SG10201912642RA (enExample)
TW (6) TW201350111A (enExample)
WO (2) WO2013110006A2 (enExample)
ZA (3) ZA201405564B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008211081A1 (en) 2007-01-31 2008-08-07 Biosuccess Biotech Company Compositions and methods of use of phorbol esters
US11696908B2 (en) 2007-01-31 2023-07-11 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters
US10369222B2 (en) 2012-01-18 2019-08-06 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters for the treatment of stroke
US11564901B2 (en) 2007-01-31 2023-01-31 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters
US9974764B2 (en) 2007-01-31 2018-05-22 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters in the treatment of neoplasms
US9533938B2 (en) 2007-01-31 2017-01-03 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters for the treatment of stroke
US9636317B2 (en) 2007-01-31 2017-05-02 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters
US9550722B2 (en) 2012-01-18 2017-01-24 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbal esters for the treatment of stroke
US10099996B2 (en) 2012-01-18 2018-10-16 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters in the treatment of neoplasms
SG10201912642RA (en) * 2012-01-18 2020-02-27 Biosuccess Biotech Co Ltd Compositions and methods of use of phorbol esters
TWI687217B (zh) * 2014-01-10 2020-03-11 華鴻新藥股份有限公司 用於中風治療之巴豆酯組成物及使用方法
NZ724799A (en) * 2014-04-16 2023-07-28 Sujon Pty Ltd Compositions and methods for the treatment or prevention of neurodegenerative disorders
JP2017527583A (ja) 2014-09-10 2017-09-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｋ−Ｒａｓによって媒介されるシグナリング経路および悪性疾患のプロストラチンによるターゲティング方法
MA40904A (fr) * 2014-11-03 2017-09-12 Hygeia Tech Inc Compositions d'ester de phorbol et procédés pour traiter ou réduire la durée d'une cytopénie
WO2016122288A2 (ko) * 2015-01-30 2016-08-04 고려대학교산학협력단 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제
KR20160107426A (ko) 2015-03-04 2016-09-19 임세영 구두 굽 및 그 제조방법
KR101710674B1 (ko) * 2015-07-22 2017-02-27 가톨릭대학교 산학협력단 Epo 수용체 및 pkc 동시 표적물질을 유효성분으로 포함하는 빈혈의 예방 또는 치료용 약학 조성물 및 이의 용도
CN106420687A (zh) * 2016-10-11 2017-02-22 孙君重 防护肠辐射损伤的方法及tpa的用途
KR102059160B1 (ko) * 2017-11-15 2019-12-24 한국생명공학연구원 다프난 또는 포볼 다이터펜계 화합물을 포함하는 신경퇴행성 질환 예방 또는 치료용 조성물
CA3084139C (en) * 2017-11-15 2023-02-28 Korea Research Institute Of Bioscience And Biotechnology Composition for preventing or treating neurodegenerative diseases, containing diterpene-based compound
CN108689851B (zh) * 2018-05-28 2020-04-17 中山大学 一类惕各烷型二萜化合物及其制备方法和应用
WO2021062030A1 (en) * 2019-09-24 2021-04-01 K-Gen, Inc. Diterpenoid compounds that act on protein kinase c (pkc)
KR102541582B1 (ko) * 2020-10-29 2023-06-12 가톨릭관동대학교산학협력단 13-ｏ-아세틸포볼을 포함하는 골질환 및 혈관석회화증 예방 또는 치료용 약학적 조성물
WO2022092884A1 (ko) * 2020-10-29 2022-05-05 가톨릭관동대학교산학협력단 13-ｏ-아세틸포볼을 포함하는 골질환 및 혈관석회화증 예방 또는 치료용 약학적 조성물
CN112715542A (zh) * 2021-01-20 2021-04-30 沈阳农业大学 巴豆烷二萜类化合物的制备方法及其在制备杀线虫的杀虫剂中的应用
CN116159126A (zh) * 2022-12-31 2023-05-26 山东大学齐鲁医院 同源二聚体介导的C/EBPαS16磷酸化通过液-液相分离调节急性髓系白血病分化

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998009523A1 (en) * 1996-09-05 1998-03-12 Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US6063814A (en) * 1997-04-14 2000-05-16 Chang; Richard L. Phorbol esters as anti-neoplastic and white blood cell elevating agents
CN1684694A (zh) * 2002-09-24 2005-10-19 菲诺斯有限公司 抑制蛋白激酶Cα用于治疗糖尿病和心血管病的组合物
US20070009529A1 (en) * 2002-03-26 2007-01-11 New York University Agents that dissolve arterial thrombi
US20110245307A1 (en) * 2002-03-07 2011-10-06 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease Treatment and Cognitive Enhancement
US20110243917A1 (en) * 2010-04-02 2011-10-06 Korea Institute Of Science And Technology Composition for the prevention and treatment of absence seizures comprising pkc agonist as an effective ingredient

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2375308A (en) 1942-08-21 1945-05-08 Ibm Method of making stencil cards
US5241051A (en) * 1992-04-24 1993-08-31 Research Development Foundation Oncoinhibin
US6184248B1 (en) * 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
WO2002083877A1 (en) * 2001-04-11 2002-10-24 Stem Cell Therapeutics Inc. Production of tyrosine hydroxylase positive neurons
CA2614110A1 (en) * 2005-07-01 2007-01-11 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
AU2008211081A1 (en) * 2007-01-31 2008-08-07 Biosuccess Biotech Company Compositions and methods of use of phorbol esters
WO2009151496A2 (en) * 2008-03-26 2009-12-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services, Induction of proliferation, effector molecule expression, and cytolytic capacity of hiv-specific cd8+ t cells
EP2331088A4 (en) * 2008-08-06 2011-10-12 Gosforth Ct Holdings Pty Ltd COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES
EP2362770A4 (en) * 2008-11-21 2012-05-30 Univ Johns Hopkins COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING RADIATION DAMAGE
RU2426535C2 (ru) * 2009-05-15 2011-08-20 Маргарита Алексеевна Морозова Применение бета-гидроксибутирата или его фармацевтически приемлемых солей для приготовления лекарственного средства, обладающего цитопротекторной активностью, включающей нейропротекторную, кардиопротекторную, противоишемическую, антигипоксическую, антистрессорную, актопротекторную и адаптогенную активности, лекарственное средство и способ профилактики, купирования и лечения с помощью этого лекарственного средства
US8575216B2 (en) * 2009-08-04 2013-11-05 Rutgers, The State University Of New Jersey Method of treatment for acute myelogenous leukemia
SG10201912642RA (en) * 2012-01-18 2020-02-27 Biosuccess Biotech Co Ltd Compositions and methods of use of phorbol esters

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998009523A1 (en) * 1996-09-05 1998-03-12 Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US6063814A (en) * 1997-04-14 2000-05-16 Chang; Richard L. Phorbol esters as anti-neoplastic and white blood cell elevating agents
US20110245307A1 (en) * 2002-03-07 2011-10-06 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease Treatment and Cognitive Enhancement
US20070009529A1 (en) * 2002-03-26 2007-01-11 New York University Agents that dissolve arterial thrombi
CN1684694A (zh) * 2002-09-24 2005-10-19 菲诺斯有限公司 抑制蛋白激酶Cα用于治疗糖尿病和心血管病的组合物
US20110243917A1 (en) * 2010-04-02 2011-10-06 Korea Institute Of Science And Technology Composition for the prevention and treatment of absence seizures comprising pkc agonist as an effective ingredient

Also Published As

Publication number Publication date
KR102102677B1 (ko) 2020-04-22
MY176593A (en) 2020-08-18
PH12020550760A1 (en) 2021-12-13
SG10201912676RA (en) 2020-02-27
HK1204447A1 (en) 2015-11-20
CA2861459A1 (en) 2013-07-25
TW202425963A (zh) 2024-07-01
MY199269A (en) 2023-10-24
IL233676A0 (en) 2014-08-31
SG10201902370QA (en) 2019-04-29
AU2020200954A1 (en) 2020-02-27
SG10201912677PA (en) 2020-02-27
RU2017140059A (ru) 2019-02-12
MX2014008773A (es) 2015-04-10
MY173042A (en) 2019-12-20
CA3077480C (en) 2023-03-14
KR20140117564A (ko) 2014-10-07
KR20140129000A (ko) 2014-11-06
MX2014008776A (es) 2015-08-20
PH12020550764A1 (en) 2021-08-16
PH12014501656A1 (en) 2014-10-13
NZ726666A (en) 2019-03-29
MY177300A (en) 2020-09-11
PH12020550768A1 (en) 2021-08-16
ZA201505443B (en) 2020-02-26
RU2650963C2 (ru) 2018-04-18
CN104507466A (zh) 2015-04-08
ZA201508059B (en) 2016-12-21
KR102102640B1 (ko) 2020-06-01
SG11201404212YA (en) 2014-10-30
CA2862301C (en) 2020-10-20
WO2014011209A1 (en) 2014-01-16
TW201934118A (zh) 2019-09-01
RU2018108884A3 (enExample) 2021-07-01
SG10201912642RA (en) 2020-02-27
BR112014017650A8 (pt) 2017-07-11
SG10201912674SA (en) 2020-03-30
SG10201912660UA (en) 2020-02-27
TW201350111A (zh) 2013-12-16
PH12020550755A1 (en) 2021-07-26
NZ727304A (en) 2018-08-31
PH12014501661A1 (en) 2014-10-20
NZ628294A (en) 2017-11-24
PH12020550765A1 (en) 2021-12-13
TWI666015B (zh) 2019-07-21
IL233674B (en) 2021-03-25
SG10201912649XA (en) 2020-02-27
CN108969514A (zh) 2018-12-11
AU2019210621A1 (en) 2019-08-22
RU2014133516A (ru) 2016-03-10
TWI817022B (zh) 2023-10-01
KR20200105731A (ko) 2020-09-08
ZA201405564B (en) 2016-02-24
IL233674A0 (en) 2014-08-31
JP2021073288A (ja) 2021-05-13
PH12014501656B1 (en) 2022-07-29
PH12020550762A1 (en) 2021-08-16
TWI664964B (zh) 2019-07-11
SG10201912667QA (en) 2020-02-27
MY192285A (en) 2022-08-17
AU2013287280B2 (en) 2016-06-30
SG10201912629UA (en) 2020-02-27
BR112014017650A2 (pt) 2021-06-08
TW201350110A (zh) 2013-12-16
TW202118485A (zh) 2021-05-16
WO2013110006A3 (en) 2015-02-05
AU2013209524A1 (en) 2014-08-14
EP2804669A4 (en) 2015-07-22
KR20190129073A (ko) 2019-11-19
JP2018203754A (ja) 2018-12-27
PH12020550759A1 (en) 2021-07-26
AU2020200954B2 (en) 2021-11-11
RU2659684C2 (ru) 2018-07-03
JP6715871B2 (ja) 2020-07-01
SG11201404211PA (en) 2014-09-26
RU2014133517A (ru) 2016-03-10
JP6835778B2 (ja) 2021-02-24
CA2862301A1 (en) 2014-01-16
CA3077480A1 (en) 2013-07-25
MX2019011333A (es) 2019-12-19
CA2861459C (en) 2020-08-25
BR112014017650B1 (pt) 2023-05-02
TW201817421A (zh) 2018-05-16
AU2013287280A1 (en) 2014-08-14
SG10201912653PA (en) 2020-02-27
AU2016203714B2 (en) 2018-01-04
JP2015513315A (ja) 2015-05-07
US20170096386A1 (en) 2017-04-06
TWI802707B (zh) 2023-05-21
EP2804601B1 (en) 2025-04-02
TW201804991A (zh) 2018-02-16
JP6463969B2 (ja) 2019-02-06
PH12020550752A1 (en) 2021-07-26
JP2015504096A (ja) 2015-02-05
CN104168957A (zh) 2014-11-26
EP2804669B1 (en) 2023-03-29
MX370146B (es) 2019-12-03
RU2017140059A3 (enExample) 2021-07-06
RU2018108884A (ru) 2019-02-26
EP2804601A4 (en) 2016-07-06
AU2016234887A1 (en) 2016-10-20
JP6336914B2 (ja) 2018-06-06
AU2019210621B2 (en) 2020-01-02
AU2016234887B2 (en) 2018-10-04
AU2016203714A1 (en) 2016-06-23
AU2017276345A1 (en) 2018-01-18
MX395719B (es) 2025-03-25
MX373291B (es) 2020-05-06
WO2013110006A2 (en) 2013-07-25
MX389510B (es) 2025-03-20
NZ628296A (en) 2017-02-24
HK1204461A1 (en) 2015-11-20
JP2018109014A (ja) 2018-07-12
NZ749356A (en) 2021-02-26
EP2804669A1 (en) 2014-11-26
EP2804601A2 (en) 2014-11-26
BR112014017716A8 (pt) 2021-03-02

Similar Documents

Publication Publication Date Title
CN110025609A (zh) 用于治疗中风的佛波醇酯的组合物和使用方法
CN109925310A (zh) 含有治疗有效量银杏内酯的降血压药物
US10143672B2 (en) Compositions and methods of use of phorbol esters for the treatment of stroke
TWI687217B (zh) 用於中風治療之巴豆酯組成物及使用方法
TWI750481B (zh) 用於中風治療之巴豆酯組成物及使用方法
US10849871B2 (en) Compositions and methods of use of phorbol esters for the treatment of stroke
US10369222B2 (en) Compositions and methods of use of phorbol esters for the treatment of stroke
HK40008510A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
JP2019519505A (ja) 血管炎症の治療または血管内皮機能の改善におけるトリアセチル−３−ヒドロキシフェニルアデノシンの応用
HK1204461B (en) Compositions and methods of use of phorbol esters for the treatment of stroke
Class et al. Patent application title: Compositions And Methods Of Use Of Phorbol Esters Inventors: Zheng Tao Han (Zhengzhou, CN) Hung-Fong Chen (Taipei, TW) Assignees: BIOSUCCESS BIOTECH CO., LTD

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40008510

Country of ref document: HK